Shamburg News · 8-K filed Oct 15, 2026, 4:26 PM EDT

Crescent Biopharma Updates Clinical Pipeline Timelines for CR-001, CR-002 and CR-003

CBIO · CRESCENT BIOPHARMA, INC.

  • Other event
  • Materiality: medium

Crescent Biopharma disclosed in an October 15, 2026 press release that it has completed dose escalation and enrolled patients in the global Phase 1/2 ASCEND trial of CR-001, with initial monotherapy data expected in the first quarter of 2027 and standard-of-care chemotherapy combination cohorts beginning enrollment. The company said the FDA cleared an IND for its topoisomerase inhibitor ADC CR-002 and that the Phase 1/2 APOLLO trial is expected to start in the fourth quarter of 2026. The filing also outlined Kelun-Biotech combination studies and planned Phase 3 CR-001 trials beginning in early 2028, contingent on results and regulator interactions.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 8.01, accession 0001628280-26-066006.

Written from the filing by Shamburg Markets. Figures are as reported by the company.